MESA, ARIZONA / ACCESS Newswire / September 2, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), an innovator in AI-powered healthcare technologies, today announced its AI Mental Health Tracker, a breakthrough solution designed to transform how anxiety, depression, and PTSD are detected and monitored. Visit the official site for more details at https://medicalcaretechnologies.com.
The. patent pending proprietary platform will leverage high-frame-rate facial landmark tracking, temporal micro-expression analysis, and emotion-recognition neural networks to uncover subclinical signs of psychological distress often missed by traditional screenings. With the ability to operate seamlessly through smartphones and webcams, this tool provides scalable, cost-effective access to real-time mental health diagnostics worldwide.
The global mental health market is valued at more than $400 billion and is expected to accelerate due to increased demand for digital therapeutics. By providing a non-invasive, AI-driven screening tool, MDCE is positioned to capture significant market share across telehealth, education, military, and workplace wellness programs.
“Mental health remains one of the most underserved areas in global healthcare,” said Marshall Perkins III. “Our AI solution has the potential to revolutionize early detection, improve access, and dramatically reduce risk.”
MDCE plans to integrate the AI Mental Health Tracker into its multi-vertical health platform, with a beta app launch targeted for 2026.
Safe Harbor Statement:
This press release contains forward-looking statements within the meaning of federal securities laws. Actual results may differ materially due to risks and uncertainties, including market conditions, regulatory approvals, and product development timelines. Medical Care Technologies Inc. undertakes no obligation to update these statements except as required by law.
Contact:
Investor Relations
Medical Care Technologies Inc.
info@infiniteauctions.com
Website: www.mdcestock.com
SOURCE: Medical Care Technologies Inc. (OTC PINK:MDCE)
View the original press release on ACCESS Newswire
Telehealth Provider Offers FDA-Approved and Compounded Weight Loss Medications in All 50 States, Subject to…
Telehealth Platform Facilitates Compounded Semaglutide and Tirzepatide Access Through Licensed Provider Evaluation as FDA Shortage…
Analysis examines best peptides for boosting growth hormone as ReadyRx lists prescription sermorelin in injectable…
Discover the best fat burner for men in 2025. Explore Wolfson Brand’s effective fat-burning supplements…
Industry Analysis Examines How Cost, Safety, and Access Considerations Shape Semaglutide Choices as MEDVi Lists…
Deploying “Proof of Human” Infrastructure throughout Japan, a Technology Envisioned by Sam Altman and Alex…